Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
Keyword(s):
2014 ◽
Vol 71
(3)
◽
pp. 484-492
◽
Keyword(s):
2019 ◽
Vol 181
(6)
◽
pp. 1177-1189
◽
Keyword(s):
Keyword(s):
Keyword(s):
2002 ◽
Vol 47
(6)
◽
pp. 821-833
◽
Keyword(s):
2007 ◽
Vol 56
(2)
◽
pp. AB5
Keyword(s):
Keyword(s):
Keyword(s):